Zhitong Finance APP reported that Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., recently received the "Approval Notification for Supplementary Application of Pharmaceutical" issued by the National Medical Products Administration regarding Cefaclor Granules (hereinafter referred to as "the product"). The company's Cefaclor Granules have added a new specification of 0.125g in addition to the existing specifications of 0.1g and 0.25g, and both the 0.125g and 0.25g specifications have passed the consistency evaluation of quality and efficacy for generic drugs, providing patients with more specification options to meet different dosing needs, which is beneficial for enhancing market competitiveness, accelerating the market promotion of Cefaclor Granules, and having a positive effect on the company's operational development.